Form 4: Stoke Therapeutics Director Sells Shares

Stoke Therapeutics Director Edward M. Kaye, MD, sold 13,430 shares of common stock for approximately $433,540 through a pre-arranged 10b5-1 trading plan.

Summary

• Edward M. Kaye, MD, a Director of Stoke Therapeutics, Inc. (STOK), sold a total of 13,430 shares of common stock.
• The sales occurred on December 8, 2025, through multiple transactions.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on December 30, 2024.
• The shares were sold at weighted average prices ranging from $31.4387 to $33.1041 per share.
• Following these transactions, Dr. Kaye beneficially owns 49,124 shares of Stoke Therapeutics common stock directly.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even if pre-planned, can be viewed with slight caution by the market, as it reduces insider ownership. However, the 10b5-1 plan mitigates the negative sentiment by indicating a scheduled, rather than reactive, sale.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not a reaction to recent negative news or a sudden change in company outlook.

Negatives

• A director selling a significant number of shares, even if pre-planned, can sometimes be perceived as a negative signal regarding future prospects or valuation by some investors.

Future Outlook

NA

Industry Context

This is an insider transaction filing and does not provide broader industry context. Insider sales are common in the biotechnology sector, particularly for long-serving directors or executives managing their personal portfolios.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, potentially influencing short-term trading sentiment.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this specific insider transaction.

Key Dates

Recommendation

While the sale by a director could be seen as a negative signal, the fact that it was executed under a pre-arranged 10b5-1 plan adopted nearly a year prior (December 2024 for a December 2025 transaction) suggests it's a personal financial planning move rather than a reaction to new, adverse company-specific information. Without additional context on the company's fundamentals or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future company developments and broader market trends.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Sale, Edward M. Kaye, Director, Stock Transaction, 10b5-1 Plan, Biotechnology